Figure 1.

eGFR change over time during empagliflozin treatment in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG-Outcome) trial and canagliflozin treatment in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial by category of percentage change in eGFR from baseline to week 4 in EMPAREG-Outcome and from baseline to week 3 in CREDENCE. In both the EMPAREG-Outcome (A) and CREDENCE trial (B), the long-term eGFR trajectories remained stable in all dipping categories. In the CREDENCE trial, long-term annual eGFR decline was slightly but statistically significantly less in patients with an acute eGFR dip (2.0 ml/min per 1.73 m² per year) compared with patients with an acute eGFR increase (2.1 ml/min per 1.73 m²; P=0.04).